Aytu BioPharma, Inc. announced the continuing availability of Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets, CII in response to numerous reported supply disruptions affecting generic Adderall® XR (mixed salts amphetamine) extended-release capsule, CII for the treatment of attention deficit hyperactivity disorder (ADHD). Adzenys XR-ODT is bioequivalent to Adderall XR and is the only FDA-approved, extended-release, orally-disintegrating tablet formulation of amphetamine. Adzenys XR-ODT is indicated for the treatment of ADHD in patients six years and older.

Aytu BioPharma has maintained consistent Adzenys XR-ODT production levels at its Grand Prairie, Texas manufacturing facility to ensure ongoing supply of Adzenys XR-ODT and has experienced no supply disruptions to date.